JNJ vs SNY vs KO

For growth investors, Sanofi (SNY) is the stronger pick with 5.

5% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). Sanofi (SNY) offers the better valuation at 18. 1x trailing P/E (10. 1x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sanofi (SNY) is the cheapest at 18.

1x versus Johnson & Johnson at 39. 4x. On forward P/E, Sanofi is actually cheaper at 10. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 17x versus Johnson & Johnson's 35. 11x.

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

3%, compared to +0. 2% for Sanofi (SNY). Over 10 years, the gap is even starker: JNJ returned +132. 2% versus SNY's +58. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Sanofi's 0. 43β — meaning SNY is approximately -283% more volatile than KO relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sanofi (SNY) is pulling ahead at 5.

5% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, SNY leads at 4. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 13. 6% for SNY. At the gross margin level — before operating expenses — SNY leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 17x versus Johnson & Johnson's 35. 11x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Sanofi (SNY) trades at 10. 1x forward P/E versus 24. 3x for The Coca-Cola Company — 14. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 20. 3% to $51. 00.

All stocks in this comparison pay dividends.

Sanofi (SNY) offers the highest yield at 5. 1%, versus 2. 1% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). Both have compounded well over 10 years (KO: +115. 0%, SNY: +58. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (JNJ (Healthcare) and SNY (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: JNJ is a large-cap quality compounder stock; SNY is a mid-cap income-oriented stock; KO is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.